Data from Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric <sup>18</sup>Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study

Purpose: To assess whether multiparametric ¹⁸fluorodeoxyglucose positron emission tomography magnetic resonance imaging (MRI) (MP ¹⁸FDG PET-MRI) using dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI), three-dimensional proton MR spectroscopic imaging (3D ¹H-MRSI), and ¹⁸FDG-PET enables an improved differentiation of benign and malignant breast tumors.

Experimental Design: Seventy-six female patients (mean age, 55.7 years; range, 25–86 years) with an imaging abnormality (BI-RADS 0, 4–5) were included in this Institutional Review Board (IRB)-approved study. Patients underwent fused PET-MRI of the breast with ¹⁸FDG-PET/CT and MP MRI at 3T. The likelihood of malignancy was assessed for all single parameters, for MP MRI with two/three parameters, and for MP ¹⁸FDG PET-MRI. Histopathology was used as the standard of reference. Appropriate statistical tests were used to assess sensitivity, specificity, and diagnostic accuracy for each assessment combination.

Results: There were 53 malignant and 23 benign breast lesions. MP ¹⁸FDG PET-MRI yielded a significantly higher area under the cure (AUC) of 0.935 than DCE-MRI (AUC, 0.86; P = 0.044) and the combination of DCE-MRI and another parameter (AUC, 0.761–0.826; P = 0.013–0.020). MP ¹⁸FDG PET-MRI showed slight further improvement to MP MRI with three parameters (AUC, 0.925; P = 0.317). Using MP ¹⁸FDG PET-MRI there would have been a reduction of the unnecessary breast biopsies recommended by MP imaging with one or two parameters (P = 0.002–0.011).

Conclusion: This feasibility study shows that MP ¹⁸FDG PET-MRI enables an improved differentiation of benign and malignant breast tumors when several MRI and PET parameters are combined. MP ¹⁸FDG PET-MRI may lead to a reduction in unnecessary breast biopsies. Clin Cancer Res; 20(13); 3540–9. ©2014 AACR.